Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novo’s Wegovy Excels But Lilly Rival Hot On Heels

Obesity Sales Up 107%

Executive Summary

After months of manufacturing blunders, the Danish major’s obesity drug has shown its blockbuster potential in the first quarter but rival Eli Lilly could soon stoke up the competition.

You may also be interested in...



Lilly Settles On Rolling Submission For Tirzepatide In Obesity

Plan for rolling submission means US FDA filing of GIP/GLP1 agonist in obesity could be complete by April 2023, setting up possibility of late 2023 approval.

Wegovy Manufacturing Issues Continue To Hamper Novo Nordisk

Danish pharma says it will not market the weight-loss formulation of semaglutide until manufacturing can meet demand. Novo has seen significant growth in GLP-1 franchise in both diabetes and obesity.

Novo’s Sogroya Impresses In Children With Convenience Advantage Over SOC

The Danish firm’s injectable growth hormone analogue has succeeded in a late-stage study of children with a growth disorder and offers more convenient dosing that could improve adherence.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146303

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel